Antibody production from hybrid cell line
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 21, 1982
Grant Date -
N/A
app pub date -
Jan 3, 1980
filing date -
Jan 9, 1979
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Hybrid cell lines for providing antibodies are produced from a rat myeloma cell line having the C.N.C.M. designation I-078. In production of the hybrid cells, the rat myeloma cell line is fused with immunocyte cells such as spleen cells from an animal such as a rat sensitized to an immunogen. Use of the rat myeloma cell line is particularly advantageous for in vivo cultivation of a hybrid cell line to produce antibodies.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully